Skip to main content
. 2023 May 17;19(6):346–362. doi: 10.1038/s41582-023-00809-y

Fig. 4. Single-cell RNA-sequencing, single-nuclei RNA-sequencing and spatial transcriptomics studies reveal cellular and molecular heterogeneity in human neurological disorders.

Fig. 4

Samples collected from the brain, spinal cord, cerebrospinal fluid (CSF) and peripheral blood have been used to analyse transcriptomes of thousands of cells and/or nuclei from individuals with multiple sclerosis (MS)87,158160, Rett syndrome (Rett S)161, Alzheimer disease (AD)60,82,84,162,163, Huntington disease (HD)164, COVID-19 (refs. 98100), amyotrophic lateral sclerosis (ALS)83,165, major depressive disorder (MDD)65, schizophrenia (SCZ)166 and autism spectrum disorders (ASD)71,167 and to compare them with healthy controls. Such an approach has also been used to compare different neurodevelopmental (Dev) stages168,169. GM, grey matter; WM, white matter.